Adma Biologics (ADMA) Other financing activities (2011 - 2025)
Adma Biologics' (ADMA) quarterly Other financing activities came in at $430000.0 in Q4 2025, up 106.1% YoY from $208638.2 in Q4 2024, and up 10.54% on a QoQ basis from $389000.0 in Q3 2025.
Adma Biologics (ADMA) Other financing activities (2011 - 2025) Analysis & Trends
Adma Biologics (ADMA) has 8 years of Other financing activities data on file, last reported at $430000.0 in Q4 2025.
- Quarterly Other financing activities rose 106.1% year-over-year to $430000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.0 million (changed N/A YoY) and the FY2025 annual result came in at $3.0 million, changed N/A from the prior year.
- Other financing activities climbed to $430000.0 in Q4 2025, from $389000.0 in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $5.7 million in Q3 2024 to a low of -$7.1 million in Q4 2024.
- A 4-year average of $490785.7 and a median of $417281.0 in 2022 frame the typical range for Other financing activities.
- Annual changes were most pronounced in 2023 — Other financing activities jumped 11011.11% — and 2024, when it slumped 88237.5%.
- Tracing ADMA's Other financing activities over 4 years: stood at $72.0 in 2022, then jumped by 11011.11% to $8000.0 in 2023, then tumbled by 88237.5% to -$7.1 million in 2024, then surged by 106.1% to $430000.0 in 2025.
- The last three Other financing activities figures came in at $430000.0 (Q4 2025), $389000.0 (Q3 2025), and $2.1 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Adma Biologics | 2.13 Bn | 2.00 Bn | 86.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 430,000.00 |
| Dec 31, 2025 | 430,000.00 |
| Sep 30, 2025 | 389,000.00 |
| Sep 30, 2025 | 389,000.00 |
| Jun 30, 2025 | 2.06 Mn |
| Jun 30, 2025 | 2.06 Mn |
| Mar 31, 2025 | 101,000.00 |
| Mar 31, 2025 | 101,000.00 |
| Dec 31, 2024 | -7.05 Mn |
| Dec 31, 2024 | -7.05 Mn |
| Sep 30, 2024 | 5.69 Mn |
| Sep 30, 2024 | 5.69 Mn |
| Jun 30, 2024 | 331,000.00 |
| Jun 30, 2024 | 331,000.00 |
| Mar 31, 2024 | 1.03 Mn |
| Mar 31, 2024 | 1.03 Mn |
| Dec 31, 2023 | 8,000.00 |
| Dec 31, 2023 | 8,000.00 |
| Sep 30, 2023 | 624,000.00 |
| Sep 30, 2023 | 624,000.00 |